NPPB and hydrops fetalis: The appraisal of clinicalutility of BNP/NTproBNP manifests in the current guidelines for the management ofheart failure.15 A number ofpublications propose Endostatin, a potent angiogenesis inhibitor, known mostly fromoncology, as a potential new HF biomarker candidate.16-18 Mostimportantly Gouya et al. reported in a prospective observational cohort study in 151HF patients, a correlation between elevated circulating Endostatin levels andmortality.